Physician profile
Danielle Baruch
NPI 1609296235
$458.93
in general payments reported to CMS, 2019-2025
12 companies · $42.10 in 2025
The $42.10 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.72 · 2020: $124 · 2021: $54.03 · 2022: $21.98 · 2023: $114 · 2024: $40.10 · 2025: $42.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $124.36 | 2020 | |
| Novartis Pharmaceuticals Corporation | $61.22 | 2021-2024 | |
| Almirall LLC | $47.80 | 2019 | |
| Lilly USA, LLC | $42.56 | 2022-2023 | Taltz, Olumiant |
| Janssen Biotech, INC. | $41.57 | 2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $31.42 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $31.29 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $20.20 | 2023 | |
| Dermavant Sciences, INC. | $16.80 | 2024 | Vtama |
| Abbvie INC. | $16.11 | 2021 | |
| Mayne Pharma Commercial LLC | $14.92 | 2019 | |
| Organon LLC | $10.68 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Baruch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.